Stephen Hoge - Feb 28, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 28, 2023
Transactions value $
-$147,963
Form type
4
Date filed
3/2/2023, 04:31 PM
Previous filing
Feb 13, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $0 +2.41K +0.15% $0.00 1.63M Feb 28, 2023 Direct F1
transaction MRNA Common Stock Sale -$148K -1.07K -0.07% $138.03 1.63M Mar 1, 2023 Direct F2
holding MRNA Common Stock 4.12K Feb 28, 2023 By Valhalla, LLC
holding MRNA Common Stock 152K Feb 28, 2023 By Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -2.41K -20% $0.00 9.64K Feb 28, 2023 Common Stock 2.41K $0.00 Direct F1, F4
transaction MRNA Stock Option (Right to Buy) Award $0 +37.2K $0.00 37.2K Feb 28, 2023 Common Stock 37.2K $138.81 Direct F5
transaction MRNA Restricted Stock Units Award $0 +9.77K $0.00 9.77K Feb 28, 2023 Common Stock 9.77K $0.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.
F5 25% of this option will vest and become exercisable on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of the shares subject to this restricted stock unit award will vest on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.